-
1
-
-
79952539202
-
Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention
-
Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther 2011;28:91-109.
-
(2011)
Adv Ther
, vol.28
, pp. 91-109
-
-
Groothuis, J.R.1
Hoopes, J.M.2
Jessie, V.G.3
-
2
-
-
71949099031
-
From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections
-
Committee on Infectious Diseases
-
Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:1694-1701.
-
(2009)
Pediatrics
, vol.124
, pp. 1694-1701
-
-
-
3
-
-
77955600570
-
Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children
-
Welliver RC Sr, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin 2010;26:2175-2181.
-
(2010)
Curr Med Res Opin
, vol.26
, pp. 2175-2181
-
-
Welliver Sr., R.C.1
Checchia, P.A.2
Bauman, J.H.3
Fernandes, A.W.4
Mahadevia, P.J.5
Hall, C.B.6
-
4
-
-
0242298724
-
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
-
Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-540.
-
(2003)
J Pediatr
, vol.143
, pp. 532-540
-
-
Feltes, T.F.1
Cabalka, A.K.2
Meissner, H.C.3
Piazza, F.M.4
Carlin, D.A.5
Top, F.H.6
-
5
-
-
16944363559
-
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
-
Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176:1215-1224.
-
(1997)
J Infect Dis
, vol.176
, pp. 1215-1224
-
-
Johnson, S.1
Oliver, C.2
Prince, G.A.3
Hemming, V.G.4
Pfarr, D.S.5
Wang, S.C.6
-
6
-
-
2142647752
-
Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease
-
Tulloh R, Marsh M, Blackburn M, Casey F, Lenney W, Weller P, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003;13:420-423.
-
(2003)
Cardiol Young
, vol.13
, pp. 420-423
-
-
Tulloh, R.1
Marsh, M.2
Blackburn, M.3
Casey, F.4
Lenney, W.5
Weller, P.6
-
7
-
-
70349406752
-
Risk factors for respiratory syncytial virus hospitalisation in children with heart disease
-
Kristensen K, Stensballe LG, Bjerre J, Roth D, Fisker N, Kongstad T, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009;94:785-789.
-
(2009)
Arch Dis Child
, vol.94
, pp. 785-789
-
-
Kristensen, K.1
Stensballe, L.G.2
Bjerre, J.3
Roth, D.4
Fisker, N.5
Kongstad, T.6
-
8
-
-
33750132530
-
Diagnosis and management of bronchiolitis
-
Subcommittee on diagnosis and management of bronchiolitis
-
Subcommittee on diagnosis and management of bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006;118:1774-1793.
-
(2006)
Pediatrics
, vol.118
, pp. 1774-1793
-
-
-
9
-
-
0033885193
-
Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: A quantitative review
-
Kneyber Mcj EW, Steyerberg R, de Groot HA, Moll HA. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. Acta Paediatr 2000;89:654-660.
-
(2000)
Acta Paediatr
, vol.89
, pp. 654-660
-
-
Kneyber, M.E.W.1
Steyerberg, R.2
de Groot, H.A.3
Moll, H.A.4
-
10
-
-
0019517639
-
Nosocomial respiratory syncytial viral infections. Should gowns and masks be used?
-
Hall CB, Douglas RG Jr. Nosocomial respiratory syncytial viral infections. Should gowns and masks be used? Am J Dis Child 1981;135: 512-515.
-
(1981)
Am J Dis Child
, vol.135
, pp. 512-515
-
-
Hall, C.B.1
Douglas Jr., R.G.2
-
11
-
-
0030959478
-
Reduction of respiratory syncytial virushospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
-
The PREVENT Study Group
-
The PREVENT Study Group. Reduction of respiratory syncytial virushospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-99.
-
(1997)
Pediatrics
, vol.99
, pp. 93-99
-
-
-
12
-
-
17944391919
-
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The cardiac study group
-
Simoes EA, Sondheimer HM, Top FH, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133:492-499.
-
(1998)
J Pediatr
, vol.133
, pp. 492-499
-
-
Simoes, E.A.1
Sondheimer, H.M.2
Top, F.H.3
Meissner, H.C.4
Welliver, R.C.5
Kramer, A.A.6
-
13
-
-
70449638239
-
Prevention of respiratory syncytial virus infection
-
Samson L. Prevention of respiratory syncytial virus infection. Paediatr Child Health 2009;14:521-32.
-
(2009)
Paediatr Child Health
, vol.14
, pp. 521-532
-
-
Samson, L.1
-
14
-
-
79952533229
-
Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis
-
Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 2011;28:110-125.
-
(2011)
Adv Ther
, vol.28
, pp. 110-125
-
-
Groothuis, J.R.1
Hoopes, J.M.2
Hemming, V.G.3
-
15
-
-
70349481698
-
Respiratory syncytial virus (RSV) prevention and treatment: Past, present, and future
-
Weisman LE. Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future. Cardiovasc Hematol Agents Med Chem 2009;7:223-233.
-
(2009)
Cardiovasc Hematol Agents Med Chem
, vol.7
, pp. 223-233
-
-
Weisman, L.E.1
-
16
-
-
78650656135
-
Respiratory syncytial virus disease: Update on treatment and prevention
-
Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther 2011;9:27-32.
-
(2011)
Expert Rev Anti Infect Ther
, vol.9
, pp. 27-32
-
-
Krilov, L.R.1
-
17
-
-
76549131273
-
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis
-
Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 2010;16:46-58.
-
(2010)
J Manag Care Pharm
, vol.16
, pp. 46-58
-
-
Frogel, M.P.1
Stewart, D.L.2
Hoopes, M.3
Fernandes, A.W.4
Mahadevia, P.J.5
-
18
-
-
0346816503
-
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections
-
Meissner HC, Long S. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112:1447-1452.
-
(2003)
Pediatrics
, vol.112
, pp. 1447-1452
-
-
Meissner, H.C.1
Long, S.2
-
19
-
-
67949109459
-
Preventing RSV bronchiolitis in vulnerable infants: The role of palivizumab
-
Fitzgerald DA. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Paediatr Respir Rev 2009;10:143-147.
-
(2009)
Paediatr Respir Rev
, vol.10
, pp. 143-147
-
-
Fitzgerald, D.A.1
-
20
-
-
77956692444
-
The cost effectiveness of palivizumab: A systematic review of the evidence
-
Smart KA, Lanctt KL, Paes BA. The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ 2010;13:453-463.
-
(2010)
J Med Econ
, vol.13
, pp. 453-463
-
-
Smart, K.A.1
Lanctt, K.L.2
Paes, B.A.3
-
21
-
-
77949403950
-
Cost effectiveness of respiratory syncytial virus prophylaxis: A critical and systematic review
-
Prescott WA, Doloresco F, Brown J, Paladino JA. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010;28:279-93.
-
(2010)
Pharmacoeconomics
, vol.28
, pp. 279-293
-
-
Prescott, W.A.1
Doloresco, F.2
Brown, J.3
Paladino, J.A.4
-
22
-
-
79958047927
-
Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications
-
2011;May 5, [Epub ahead of print]
-
Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 2011;May 5. [Epub ahead of print]
-
Arch Pediatr Adolesc Med
-
-
Hampp, C.1
Kauf, T.L.2
Saidi, A.S.3
Winterstein, A.G.4
-
23
-
-
0037232387
-
Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection
-
Lacaze-Masmonteil T, Seidenberg J, Mitchell I, Cossey V, Cihar M, Csader M, et al. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf 2003;26:283-291.
-
(2003)
Drug Saf
, vol.26
, pp. 283-291
-
-
Lacaze-Masmonteil, T.1
Seidenberg, J.2
Mitchell, I.3
Cossey, V.4
Cihar, M.5
Csader, M.6
-
24
-
-
28044466643
-
Safety and immunogenicity of palivizumab (Synagis) administered for two seasons
-
Null D, Pollara B, Dennehy PH, Steichen J, Snchez PJ, Givner LB, et al. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 2005;24:1021-1023.
-
(2005)
Pediatr Infect Dis J
, vol.24
, pp. 1021-1023
-
-
Null, D.1
Pollara, B.2
Dennehy, P.H.3
Steichen, J.4
Snchez, P.J.5
Givner, L.B.6
-
25
-
-
77954706646
-
Palivizumab-resistant human respiratory syncytial virus infection in infancy
-
Adams O, Bonzel L, Kovacevic A, Mayatepek E, Hoehn T, Vogel M. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis 2010;51:185-188.
-
(2010)
Clin Infect Dis
, vol.51
, pp. 185-188
-
-
Adams, O.1
Bonzel, L.2
Kovacevic, A.3
Mayatepek, E.4
Hoehn, T.5
Vogel, M.6
-
26
-
-
4344651091
-
Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants
-
DeVincenzo JP, Hall CB, Kimberlin DW, Snchez PJ, RodriguezWJ, Jantausch BA, et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 2004;190:975-978.
-
(2004)
J Infect Dis
, vol.190
, pp. 975-978
-
-
Devincenzo, J.P.1
Hall, C.B.2
Kimberlin, D.W.3
Snchez, P.J.4
Rodriguez, W.J.5
Jantausch, B.A.6
-
28
-
-
78649683045
-
Treatment of respiratory syncytial virus with palivizumab: A systematic review
-
Hu J, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World J Pediatr 2010;6:296-300.
-
(2010)
World J Pediatr
, vol.6
, pp. 296-300
-
-
Hu, J.1
Robinson, J.L.2
-
30
-
-
70349376986
-
Motavizumab for the prevention of respiratory syncytial virus infection in infants
-
Gill MA, Welliver RC. Motavizumab for the prevention of respiratory syncytial virus infection in infants. Expert Opin Biol Ther 2009;9:1335-1345.
-
(2009)
Expert Opin Biol Ther
, vol.9
, pp. 1335-1345
-
-
Gill, M.A.1
Welliver, R.C.2
-
31
-
-
0014493107
-
Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine
-
Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969;89:435-448.
-
(1969)
Am J Epidemiol
, vol.89
, pp. 435-448
-
-
Fulginiti, V.A.1
Eller, J.J.2
Sieber, O.F.3
Joyner, J.W.4
Minamitani, M.5
Meiklejohn, G.6
-
32
-
-
0023801538
-
Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity
-
Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988;26:1595-1597.
-
(1988)
J Clin Microbiol
, vol.26
, pp. 1595-1597
-
-
Murphy, B.R.1
Walsh, E.E.2
-
33
-
-
38449084342
-
CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease
-
Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol 2007;179:5415-5424.
-
(2007)
J Immunol
, vol.179
, pp. 5415-5424
-
-
Olson, M.R.1
Varga, S.M.2
-
35
-
-
70350515701
-
Respiratory syncytial virus vaccine development
-
Murata Y. Respiratory syncytial virus vaccine development. Clin Lab Med 2009;29:725-739.
-
(2009)
Clin Lab Med
, vol.29
, pp. 725-739
-
-
Murata, Y.1
-
36
-
-
77956685320
-
New insights for development of a safe and protective RSV vaccine
-
Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum Vaccin 2010;6:482-492.
-
(2010)
Hum Vaccin
, vol.6
, pp. 482-492
-
-
Blanco, J.C.1
Boukhvalova, M.S.2
Shirey, K.A.3
Prince, G.A.4
Vogel, S.N.5
|